Hepion Pharmaceuticals, Inc. director James Gordon Liddy received a grant of 510,000 stock options on October 23, 2026, with an exercise price of $0.14 per share for common stock. The options vest in equal amounts of 42,500 monthly over 12 months from the grant date. His reported direct option holdings following the grant were 809,000; the options expire October 23, 2036.
Hepion Pharmaceuticals, Inc. director Danina Fisher received an award of 510,000 stock options to acquire common stock on October 23, 2026. The options have an exercise price of $0.14 per share and expire October 23, 2036. The vesting note states that 42,500 options vest in equal amounts monthly over 12 months from the grant date.
Hepion Pharmaceuticals, Inc. (HEPA) Chief Financial Officer Gary S. Stetz received an award of 1,530,000 stock options on October 23, 2026, with an exercise price of $0.14 per share. The options vest in equal monthly amounts of 127,500 over 12 months from the grant date. His reported option holdings following the award were 2,875,500.
Hepion Pharmaceuticals, Inc. Executive Chairman Vincent S. LoPriore was granted 1,530,000 stock options on October 23, 2026. The options have an exercise price of $0.14 per share and expire October 23, 2036. LoPriore's reported direct option holdings following the award were 2,875,500.
Hepion Pharmaceuticals, Inc. (HEPA) director Michael J. Purcell received a grant of 510,000 stock options on October 23, 2026. The options have an exercise price of $0.14 per share and expire October 23, 2036. They vest in equal monthly installments of 42,500 options over 12 months from the grant date. Purcell’s reported stock-option holdings following the award were 809,000.
Hepion Pharmaceuticals, Inc. Chief Executive Officer Sireesh Appajosyula received a grant of 1,530,000 stock options on October 23, 2026. The options have an exercise price of $0.14 per share and expire October 23, 2036. The reported direct option position after the grant is 2,875,500 options; 127,500 options vest in equal amounts monthly over 12 months from the grant date.
Hepion Pharmaceuticals, Inc. VP, Corp. Dev. Chase LoPriore received a grant of 1,530,000 stock options on October 23, 2026. The options have an exercise price of $0.14 per share and expire on October 23, 2036. His reported direct option holdings following the grant were 2,875,500. The footnote states that 127,500 options vest in equal amounts monthly over 12 months from the grant date.
Hepion Pharmaceuticals, Inc. (HEPA) director Gary S. Stetz II received a grant of stock options covering 510,000 shares of common stock on October 23, 2026, with an exercise price of $0.14 per share. The options vest in equal monthly amounts of 42,500 over 12 months from the grant date. His reported options position following the grant was 809,000.
Hepion Pharmaceuticals, Inc. (HEPA) common stock was acquired by Gravitas Collective Corp., which received 25,000,000 shares on October 6, 2026, in exchange for the membership interests of Gravitas Life Sciences, Inc., which Gravitas Collective solely owned. Gravitas Collective reported beneficial ownership of 25,000,000 shares, equal to 19.9% of the class, with sole voting and dispositive power. The percentage was based on 125,073,217 Hepion common shares outstanding as of October 6, 2026. Gravitas Collective said it acquired the shares for investment purposes and may make further acquisitions from time to time; it reported no other plans or proposals relating to the other matters covered by its disclosure.
Hepion Pharmaceuticals, Inc. is the issuer in an amended Schedule 13G reporting Kenneth Rickel’s beneficial ownership of 7,250,000 shares, or 7.2% of the class. The reported amount includes 2,000,000 shares issuable upon exercise of warrants. The ownership percentage uses 98,220,317 shares of common stock outstanding as of August 31, 2026. Rickel reported sole voting and dispositive power over 7,250,000 shares, with shared voting and dispositive power of zero.